AstraZeneca Pharma India is undertaking a recall of sterile products manufactured at its facility in Bangalore, following an internal audit conducted by the company. This recall is a purely voluntary action on the part of the company taken as a measure of extra and abundant caution although there is no patient safety issue reported relating to sterility.
The company firmly believes that the health and safety of the end users of these products is of paramount and overriding importance. With this the company is ensuring that international quality standards are maintained globally on a consistent basis.
Further, a temporary interruption of supplies of affected products is expected. The company is also exploring all options to resume quality supplies of its sterile products at the earliest opportunity.
AstraZeneca Pharma India is engaged in the business of manufacturing and marketing pharmaceutical products in healthcare segments namely gastrointestinal, cardiovascular, cancer, respiratory, neurosciences and infection.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: